Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

HDAC inhibitors and cancer therapy.

Atadja PW.

Prog Drug Res. 2011;67:175-95. Review.

PMID:
21141730
2.

Development of histone deacetylase inhibitors for cancer treatment.

Marchion D, M√ľnster P.

Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. Review.

PMID:
17428177
3.

Histone deacetylase inhibitors in cancer therapy.

Lane AA, Chabner BA.

J Clin Oncol. 2009 Nov 10;27(32):5459-68. doi: 10.1200/JCO.2009.22.1291. Epub 2009 Oct 13. Review.

PMID:
19826124
4.

Histone deacetylases: target enzymes for cancer therapy.

Mottet D, Castronovo V.

Clin Exp Metastasis. 2008;25(2):183-9. Epub 2007 Dec 5. Review.

PMID:
18058245
5.

Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.

Hadnagy A, Beaulieu R, Balicki D.

Mol Cancer Ther. 2008 Apr;7(4):740-8. doi: 10.1158/1535-7163.MCT-07-2284. Review.

6.

Histone deacetylase inhibitors in cancer treatment.

Vigushin DM, Coombes RC.

Anticancer Drugs. 2002 Jan;13(1):1-13. Review.

PMID:
11914636
7.

Chemical origins of isoform selectivity in histone deacetylase inhibitors.

Butler KV, Kozikowski AP.

Curr Pharm Des. 2008;14(6):505-28. Review.

PMID:
18336297
8.

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

Santini V, Gozzini A, Ferrari G.

Curr Drug Metab. 2007 May;8(4):383-93. Review.

PMID:
17504226
9.

Acetylation of proteins as novel target for antitumor therapy: review article.

Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A.

Amino Acids. 2004 Jul;26(4):435-41. Epub 2004 Jun 11. Review.

PMID:
15290351
10.

The role of histone deacetylases (HDACs) in human cancer.

Ropero S, Esteller M.

Mol Oncol. 2007 Jun;1(1):19-25. doi: 10.1016/j.molonc.2007.01.001. Epub 2007 Mar 7. Review.

11.

Inhibition of histone deacetylases.

Huang Y, Shaw PG, Davidson NE.

Methods Mol Biol. 2011;791:297-311. doi: 10.1007/978-1-61779-316-5_22.

PMID:
21913088
12.

Histone deacetylase inhibitors--a new tool to treat cancer.

Somech R, Izraeli S, J Simon A.

Cancer Treat Rev. 2004 Aug;30(5):461-72.

PMID:
15245778
13.

Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.

Balakin KV, Ivanenkov YA, Kiselyov AS, Tkachenko SE.

Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. Review.

PMID:
17896917
14.

Reversal of gene silencing as a therapeutic target for cancer--roles for DNA methylation and its interdigitation with chromatin.

Baylin SB.

Novartis Found Symp. 2004;259:226-33; discussion 234-7, 285-8. Review.

PMID:
15171257
15.

Histone deacetylases and cancer: causes and therapies.

Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK.

Nat Rev Cancer. 2001 Dec;1(3):194-202. Review.

PMID:
11902574
16.

Role of histone deacetylase inhibitors in the treatment of cancer (Review).

Mei S, Ho AD, Mahlknecht U.

Int J Oncol. 2004 Dec;25(6):1509-19. Review.

PMID:
15547685
17.

Epigenetic regulation of gene expression as an anticancer drug target.

Ferguson LR, Tatham AL, Lin Z, Denny WA.

Curr Cancer Drug Targets. 2011 Feb;11(2):199-212.

PMID:
21158714
18.

Histone acetylation and the cell-cycle in cancer.

Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG.

Front Biosci. 2001 Apr 1;6:D610-29. Review.

PMID:
11282573
19.

Histone deacetylase inhibitors in cancer therapy.

Rasheed WK, Johnstone RW, Prince HM.

Expert Opin Investig Drugs. 2007 May;16(5):659-78. Review.

PMID:
17461739
20.

Histone deacetylase inhibitors as new cancer drugs.

Marks PA, Richon VM, Breslow R, Rifkind RA.

Curr Opin Oncol. 2001 Nov;13(6):477-83. Review.

PMID:
11673688

Supplemental Content

Support Center